Investors in Life Science

Forbion is a leading European venture capital firm that helps companies bridge research and development through the team’s expertise in drug development and company building. Forbion is signatory to the United Nations Principles for Responsible Investment further demonstrating our philosophy that investments in companies should positively impact the health and well-being of patients.

Adjuvo is an experienced membership network of Angel investors who support and commit capital to innovative early-stage British companies. From former Directors of large public companies to successful founders and entrepreneurs, our membership consists of over 170 individuals with expertise across private and public industry sectors and organisations of scale. With a portfolio of over 20 businesses, potential portfolio companies will be innovative, high-growth businesses led by outstanding founders who have the desire to work collaboratively with us and other co-investors.

BonVenture is the first investment company in the German-speaking region that focuses on the social impact of companies. Since 2003, we have offered investors the opportunity to allocate social venture capital to social enterprises through our funds. As partner of social entrepreneurs, we strengthen them with capital, know-how and contacts and provide guidance in setting up and growing their organization. This is how we promote the development and establishment of social innovations at scale. Since 2014, we are the first German fund manager to be officially EuSEF-registered (EU REGULATION FOR SOCIAL ENTREPRENEURSHIP).

We are a global venture capital firm founded in 2010. We manage over $1.25 billion across nine funds, with offices in Tel Aviv, London and New York. We believe in exceptional founders and invest in a wide range of sectors including AI, Data, DeepTech, FinTech, Cyber, SaaS, and Crypto, providing support to innovative startups from pre-seed to growth stages. In our portfolio you can find more than 180 high-profile companies, including monday.com, Riskified, Rapyd, Coupang, HiBob, Gusto, Talon Cyber, Breezometer, Glovo, Bluewhite Robotics, Stripe, NVision, Stash, Mesh Payments, Perimeter81, PillPack, and many more. Over the yeras, we exited or IPO’d over 33 companies, with significant IPO’s including Deliveroo, Coupang, Riskified, monday.com, Talon Cyber and Perimeter 81.

InHealth Ventures (IHV) is a London-based early stage venture capital fund investing in tech-enabled healthcare and life sciences. We back founders working to reengineer healthcare, and use our deep experience, strategic insights and global network to accelerate their journey from Seed to Series A and beyond. IHV’s mission is to contribute to bending the healthcare cost curve, improving patient access and outcomes while enhancing the working lives of clinical and non-clinical staff.

AlbionVC supports visionary founders with long-term capital and scale-up expertise. Founded in 1996, today we are partners to UK early-stage software, healthcare and deeptech companies. AlbionVC manages c. $1 billion of venture funds, currently invested in over 50 companies. AlbionVC is the technology investment arm of Albion Capital Group LLP, which is authorised and regulated by the Financial Conduct Authority.

The first NHS-founded and backed venture fund for digital health and MedTech. Accelerating the future of healthcare in the UK and beyond.

Gilde Healthcare is a specialized healthcare investor managing over €2.6 billion across two fund strategies: Venture&Growth and Private Equity. Gilde Healthcare is headquartered in Utrecht (the Netherlands) with local offices in Frankfurt (Germany) and Boston (USA). Gilde Healthcare differentiates itself through its deep sector knowledge in healthcare, which has been acquired during the past decades. The investment team consisting of industry experts, ex-consultants and investors provides hands-on support to its managers in designing the growth strategy and by contributing domain expertise. Gilde Healthcare believes optimal value creation in healthcare is associated with better care at lower cost.

STOAF, is an early stage VC fund, registered as an AIF under the EuVECA framework. Started in 2008, STOAF is now operating its third fund, STOAF III SciTech. The focus is on early stage investments in sustainable research based spin-outs within deep tech and life sciences.

The Joint Polish Investment Fund, ("JPIF") is a new Life Science Venture Capital Fund, which focuses on investments in Life Science companies with visible and near-term value inflection points and a prospective holding period of 3-5 years. JPIF consists of a team of people with broad experience in the life-science sector. Scientists and medical doctors with industrial experience work hand in glove with colleagues who have a thorough training in economics and business affairs. Everybody is driven by true interest in the life science field and new technologies, which will greatly contribute to people’s health disease management and quality of life. Entrepreneurs backed by JPIF have access to the knowledge and advice of each member of the JPIF team and to the associated global scientific and commercial network. Together JPIF and entrepreneurs are therefore in the position to accelerate preclinical, clinical or commercial development and a successful market entry into the most important healthcare markets: Europe, the U.S., and Asia.

The Merantix AI Fund builds and invests in category-defining early-stage AI-native companies, always seeking the largest exponential lever through AI as a general-purpose technology. We strongly believe in and focus on vertically integrated business models, data flywheel effects, multidisciplinary founding teams, societal impact, and leveraging the European industry sovereignty.